DMAA Drugs Made In America Acquisition Corp.

NAS · US · Financial Services · Shell Companies

10.84USD-0.46%Mkt Cap: 263.16M $P/E: 60.221d ago

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business …

Industry Peers

Shell Companies

Armada Acquisition Corp. II

$790.07MUSDP/E 227.4

DMII

Drugs Made In America Acquisition II Corp.

$649.10MUSDP/E 34.0

CCXI

Churchill Capital Corp XI

$626.07MUSD

EVAC

EQV Ventures Acquisition Corp. II

$602.60MUSDP/E 34.4

BCSS

Bain Capital GSS Investment Cor

$596.85MUSD

CXII

Churchill Capital Corp XII

$591.61MUSD

CEPF

Cantor Equity Partners IV, Inc.

$586.93MUSDP/E 31.1

AC8

Intuitive Investments Group Plc

$532.06MUSDP/E 2.5

AEXA

American Exceptionalism Acquisition Corp. A

$536.65MUSD

NWAX

New America Acquisition I Corp.

$500.24MUSD

AAC

Ares Acquisition Corporation III

$496.66MUSD

MLAA

Mountain Lake Acquisition Corp. II

$490.34MUSD

KRSP

Rice Acquisition Corporation 3

$486.71MUSD

BRTM

B&R Technology Merger Corp.

$478.69MUSD

CRAN

Crane Harbor Acquisition Corp. II

$473.69MUSD

GTEN

Gores Holdings X, Inc.

$470.58MUSDP/E 21.3

GCGR

General Catalyst Global Resilience Merger Corp.

$467.87MUSD

APXT

Apex Treasury Corporation

$466.49MUSD

BCCQ

Bleichroeder Acquisition Corp. III

$457.24MUSD

Key Statistics

Company

Market Cap263.16M USD

Enterprise Value264.71M USD

Revenue (TTM)—

Gross Profit—

Net Income (TTM)5.94M USD

Revenue/Share—

Last Price10.84 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees—

CountryUS

SectorFinancial Services

IndustryShell Companies

ISIN—

Valuation

P/E (Trailing)60.22

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B-35.70

EPS (TTM)0.18

EPS (Forward)—

52W Range

10.2692% of range10.89

52W High10.89 USD

52W Low10.26 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE2.55%

ROA2.48%

Growth

Revenue Growth—

Earnings Growth-17.90%

Cash Flow & Leverage

Operating CF-539.19K USD

CapEx (TTM)—

FCF Margin—

FCF Yield—

Net Debt329.72K USD

Net Debt/EBITDA—

Balance Sheet

Debt/Equity—

Current Ratio0.02

Quick Ratio0.01

Book Value/Sh-0.30 USD

Cash/Share0.0010 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.24.28M

Float19.79M

Insiders23.57%

Institutions53.43%

Short Interest

Short Ratio2.0d

Short % Float0.47%

Short % Out.0.38%

Shares Short92.52K

Short (prev mo.)80.59K

Technical

SMA 5010.77 (+0.6%)

SMA 20010.59 (+2.4%)

Beta—

S&P 52W Chg16.45%

Avg Vol (30d)30.10K

Avg Vol (10d)460

Technical Indicators

RSI (14)53.9

MACD0.0297

MACD Signal0.0325

MACD Hist.-0.0028

BB Upper10.91 USD

BB Middle10.85 USD

BB Lower10.79 USD

BB Width1.07%

ATR (14)0.0210 USD

Vol Ratio (20d)1.06x